Robert Carruthers
University of British Columbia
Internal medicinePathologyMagnetic resonance imagingPediatricsFingolimodOptic neuritisSpectrum disorderMyelinDiseaseComorbidityMultiple sclerosisExpanded Disability Status ScaleNatalizumabNeuromyelitis opticaPopulationConfidence intervalFamily medicineMedicineCohort
Publications 55
#1Lisa Eunyoung Lee (UBC: University of British Columbia)H-Index: 4
#2Irene M. Vavasour (UBC: University of British Columbia)H-Index: 30
Last. Shannon H. Kolind (UBC: University of British Columbia)H-Index: 25
view all 20 authors...
Background:Myelin water imaging (MWI) was recently optimized to provide quantitative in vivo measurement of spinal cord myelin, which is critically involved in multiple sclerosis (MS) disability.Ob...
#1Magdalena A. Wirth (UBC: University of British Columbia)
Last. Claire A. SheldonH-Index: 17
view all 8 authors...
Purpose To determine whether optical coherence tomography angiography is of diagnostic utility for Susac syndrome (SuS) by quantifying microvascular retinal changes. Methods We enrolled 18 eyes of 9 healthy controls and 18 eyes of 9 patients with chronic SuS (12 had previous branch retinal artery occlusions and 6 were clinically unaffected). Images of the fovea were taken using an optical coherence tomography angiography system. Analysis included vessel density, fractal dimension, vessel diamete...
#1Gillian Paton (UBC: University of British Columbia)H-Index: 1
#2Claire A. Sheldon (UBC: University of British Columbia)H-Index: 17
Last. Robert Carruthers (UBC: University of British Columbia)H-Index: 12
view all 7 authors...
Abstract Objective To evaluate whether corpus callosum (CC) lesions are inextricably linked to CNS symptoms of Susac Syndrome (SuS) by reviewing published cases to find instances where: 1) CC lesions occur without CNS symptoms, and 2) whether patients with CNS symptoms lack CC lesions. Methods 100 reported cases of SuS were identified in PubMed. Clinical symptoms, para-clinical testing and MRI data were collected both at presentation and for any available follow-up and analyzed. Cases were revie...
#1Helen Cross (UBC: University of British Columbia)H-Index: 1
#2Farahna Sabiq (UBC: University of British Columbia)
Last. Anthony Traboulsee (UBC: University of British Columbia)H-Index: 42
view all 16 authors...
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease is a recently described central nervous system (CNS) inflammatory disorder with phenotypic overlap with Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD seronegative patients, and those with limited forms of the disorder, become suspects for MOG antibody-associated disease. We describe a multi-ethnic population with MOG antibody seropositivity from the University of British Columbia MS/NMO clinic. AQP4-antibody seronegati...
#1Elaine Kingwell (UCL: University College London)H-Index: 1
#1Elaine Kingwell (UCL: University College London)H-Index: 24
Last. Helen Tremlett (UBC: University of British Columbia)H-Index: 45
view all 8 authors...
BACKGROUND Real-world safety data for the oral multiple sclerosis (MS) disease-modifying therapies (DMTs), dimethyl fumarate (DMF), fingolimod, and teriflunomide are important. We examined laboratory test abnormalities and adverse health conditions in new users. METHODS Linked laboratory and administrative health data were accessed for all persons with MS (PwMS) filling their first oral DMT prescription in two Canadian provinces. PwMS were followed from first prescription fill until discontinuat...
#1Tingting Zhang (Harvard University)H-Index: 1
#2Matthew GoodmanH-Index: 2
Last. Zongqi XiaH-Index: 17
view all 11 authors...
2 CitationsSource
#1Amit Bar-Or (UPenn: University of Pennsylvania)H-Index: 79
#2Jeffrey L. Bennett (CU: University of Colorado Boulder)H-Index: 51
Last. Anne H. Cross (WashU: Washington University in St. Louis)H-Index: 70
view all 26 authors...
Objective: To assess longitudinal changes in B cells, T cells, neurofilament light (NfL) and soluble inflammatory markers in patients with primary progressive (PPMS) and relapsing (RMS) multiple sclerosis following ocrelizumab (OCR) treatment. Background: OCR, an anti-CD20 molecule, reduces progression in MS. Less is known about biomarkers and mechanisms of anti-CD20 action in PPMS than in RMS. Presence of T1 gadolinium–enhancing lesions has been associated with higher baseline cerebrospinal flu...
#1Huah Shin Ng (UBC: University of British Columbia)H-Index: 4
#2Elaine Kingwell (UBC: University of British Columbia)H-Index: 24
Last. Helen Tremlett (UBC: University of British Columbia)H-Index: 45
view all 7 authors...
Objective:To examine laboratory testing adherence by persons initiating an oral disease-modifying therapy (DMT) for multiple sclerosis (MS).Methods:Population-based health administrative and labora...
3 CitationsSource
#1Shawna Abel (UBC: University of British Columbia)H-Index: 2
#2Irene M. Vavasour (UBC: University of British Columbia)H-Index: 30
Last. Shannon H. Kolind (UBC: University of British Columbia)H-Index: 25
view all 22 authors...
BACKGROUND AND PURPOSE: Cognitive impairment is a core symptom in multiple sclerosis (MS). Damage to normal appearing white matter (NAWM) is likely involved. We sought to determine if greater myelin heterogeneity in NAWM is associated with decreased cognitive performance in MS. METHODS: A total of 27 participants with MS and 13 controls matched for age, sex, and education underwent myelin water imaging (MWI) from which the myelin water fraction (MWF) was calculated. Corpus callosum, superior lon...
4 CitationsSource
BACKGROUND: Patients with multiple sclerosis (MS) experience progressive thinning in optical coherence tomography (OCT) measures of neuroaxonal structure regardless of optic neuritis history. Few prospective studies have investigated the effects of disease-modifying therapies on neuroaxonal degeneration in the retina. Alemtuzumab is a monoclonal antibody shown to be superior to interferon β-1a in treating relapsing-remitting MS (RRMS). The purpose of this study was to assess the effects of alemt...